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GSSGErythrocytes are both an important source and target of reactive oxygen species in sickle cell disease. Levels of
glutathione, a major antioxidant, have been shown to be decreased in sickle erythrocytes and the mechanism
leading to this deﬁciency is not known yet. Detoxiﬁcation of reactive oxygen species involves the oxidation of
reduced glutathione (GSH) into glutathione-disulﬁde (GSSG) which is actively transported out of erythrocyte.
We questioned whether under oxidative conditions, GSSG efﬂux is increased in sickle erythrocytes.
Erythrocytes of 18 homozygous sickle cell patients and 9 race-matched healthy controls were treated with
2,3-dimethoxy-l,4-naphthoquinone,which induces intracellular reactive oxygen species generation, to stimulate
GSSGproduction. Intra- and extracellular concentrations of GSH andGSSGweremeasured at baseline and during
210-minute 2,3-dimethoxy-l,4-naphthoquinone stimulation. While comparable at baseline, intracellular and
extracellular GSSG concentrations were signiﬁcantly higher in sickle erythrocytes than in healthy erythrocyte
after 210-minute 2,3-dimethoxy-l,4-naphthoquinone stimulation (69.9±3.7 μmol/l vs. 40.6±6.9 μmol/l and
25.8±2.7 μmol/l vs. 13.6±1.7 μmol/l respectively, Pb0.002). In contrast to control erythrocytes, where GSH
concentrations remained unchanged (176±8.4 μmol/l vs. 163±13.6 μmol/l, NS), GSH in sickle erythrocytes
decreased signiﬁcantly (from 167±8.8 μmol/l to 111±11.8 μmol/l, Pb0.01) after 210-minute 2,3-dimethoxy-
l,4-naphthoquinone stimulation. Adding multidrug resistance-associated protein-1 inhibitor (MK571) to
erythrocytes blocked GSSG efﬂux in both sickle and normal erythrocytes. GSSG efﬂux, mediated by multidrug
resistance-associated protein-1, is increased in sickle erythrocytes, resulting in net loss of intracellular
glutathione and possibly higher susceptibility to oxidative stress.dicine, Slotervaart Hospital,
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Oxidative stress plays a major role in the pathophysiology of sickle
cell disease (SCD), contributing signiﬁcantly to hemolysis, hypercoa-
gulability, endothelial activation, decreased nitric oxide (NO) bio-
availability and organ damage [1–6]. One of the important sources of
oxidative stress in SCD are sickle erythrocytes, where the unstable
autoxidative sickle hemoglobin (HbS) and increased metabolic
turnover due to recurrent HbS polymerizations and depolymeriza-
tions cause increased generation of reactive oxygen species (ROS)
[7,8]. The higher energy expenditure due to the increased metabolic
turnover upon polymerization and depolymerization results in higher
ROS production in sickle erythrocytes [8,9].
The increased and unremitting generation of ROS in SCD results
in excessive consumption and thus deﬁciency of antioxidants, such
as glutathione [8,10,11]. In its reduced form (GSH), glutathione
(glycyl-cysteinyl-γ-glutamate) is a major intracellular antioxidant
Table 1
Red blood cell parameters.
Patients (n=18) Controls (n=9) P
Erythrocytes (×1012/l) 2.76 (2.41–3.25) 4.77 (4.11–5.12) b0.0001
Hemoglobin (g/dl) 9.0 (8.5–9.5) 13.2 (12.6–14.5) b0.0001
Hematocrit (l/l) 0.25 (0.24–0.27) 0.39 (0.37–0.43) b0.0001
MCV (ﬂ) 88.8 (82.5–94.8) 85.1 (83.2–89.1) 0.5
MCH (pg/cell) 30.5 (28.0–34.5) 29.2 (27.1–30.6) 0.2
MCHC (g/dl) 35.1 (34.3–35.8) 34.0 (33.5–34.6) 0.005
Values are median (interquartile range).
MCV=mean corpuscular volume, MCH=mean corpuscular hemoglobin, MCHC=mean
corpuscular hemoglobin concentration.
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of GSH into glutathione disulﬁde (GSSG). The intracellular glutathione
concentration is the ﬁnal result of a balance between GSH generation
(via de novo synthesis and recycling from GSSG by glutathione
reductase) and the combined rate of GSH consumption by ROS and
excretion of the resulting GSSG [16,17]. Under normal conditions 95%
of the intracellular glutathione is present in its reduced GSH form [15].
The oxidized GSSG form can either be recycled to GSH or removed
from the intracellular environment through specialized transporters,
such as multidrug resistance-associated protein-1 (MRP1, encoded by
the ABCC1 gene), located in erythrocyte cell membrane [18,19].
In SCD, the mechanism for erythrocyte glutathione deﬁciency has
not been determined yet. GSH production in sickle erythrocytes,
through de novo synthesis and recycling, has been shown to be higher
as compared to healthy erythrocytes [11], and canbe further augmented
by supplying the thiol compoundsN-acetylcysteine (amide) [20,21].We
questioned whether the decreased glutathione concentrations in sickle
erythrocytes are caused by a net loss of glutathione through a higher
efﬂux of GSSG from the intracellular environment. To test this
hypothesis, we stressed erythrocytes of sickle cell patients and healthy
race-matched controls with 2,3-dimethoxy-l,4-naphthoquinonethe
(DMNQ) and hydrogen peroxide (H2O2) in vitro. DMNQ cannot
conjugate with GSH directly but it participates in redox reactions,
resulting in continuous intracellular generation of ROS, thereby
inducing oxidation of GSH to GSSG [22]. To determine the differences
in GSSG production and efﬂux between sickle and healthy erythrocytes,
glutathione concentrations were measured both in erythrocytes and
extracellular supernatant respectively.
2. Materials and methods
2.1. Materials
5,5′-Dithiobis-2-nitrobenzoic acid (DTNB), N-Ethylmaleimide
(NEM) and Triton X 100 were purchased from Sigma-Aldrich, Inc.,
nicotinamide adenine dinucleotide phosphate (NADPH) and gluta-
thione reductase from Roche Diagnostics (Mannheim, Germany),
perchloric acid (PCA) from Merck Chemicals, Inc., and MK571 from
Enzolifesciences (Zandhoven, Belgium).
2.2. Study population
Eighteen adult patients with sickle cell anemia (HbSS), (age,
median+range: 27 [19–56], male/female 10/8) from the outpatient
clinic of Academic Medical Center (AMC) and 9 race- and gender-
matched healthy controls (age, 41 [29–61]; male/female, 5/4) were
included in the study. Inclusion criteria were age≥18 years and high
performance liquid chromatography (HPLC) conﬁrmed genotypes of
HbSS (patients) and normal HbAA hemoglobin (healthy controls) and
exclusion criteria were vaso-occlusive pain crisis and blood trans-
fusions in the preceding 1 and 4 months respectively, active in-
fections, auto-immune inﬂammatory diseases and diabetes. All
participants received verbal and written explanation of the objectives
and procedure of the study and subsequently provided written
informed consent. The study was approved by the AMC Medical
Ethical Commission and experiments were performed in accordance
with the Declaration of Helsinki.
2.3. Erythrocyte preparation
Peripheral blood was obtained via venipuncture in EDTA tubes
(7 ml; BD Vacutainer Systems, Plymouth, UK). Hematological indices,
including erythrocyte counts, hemoglobin, hematocrit, mean corpus-
cular volume (MCV), mean corpuscular hemoglobin (MCH), andmean
corpuscular hemoglobin concentration (MCHC), were measured on a
fully automated hematology analyzer (XE-5000; Sysmex Corp.)within 15 minutes after drawing blood (Table 1). After centrifugation
at 1700×g (4 °C) for 5 minutes, erythrocytes were washed twice with
phosphate-buffered saline (PBS; Biological Industries, Bet-Haemek,
Israel). While MCV was comparable between sickle and healthy
erythrocytes, sickle cell patients had signiﬁcantly lower hemoglobin
concentrations and erythrocyte counts. Therefore, the cell pellet of
erythrocytes was resuspended in Hank's Buffered Salt Solution (HBSS,
ScienCell, CA,USA) to a standardized erythrocyte concentration of
5.0×1012/liter. The erythrocyte suspension was divided in 16 equal
volumes for duplicate measurements of extra- and intracellular
glutathione concentrations at 4 time points. Baseline samples were
processed immediately and after adding 10 μMDMNQ, the samples of
the other 3 time points were incubated (37 °C) for 90, 150 and
210 minutes, respectively. To test GSSG efﬂux in two independent
mechanisms of oxidative stress, sickle and healthy erythrocytes were
also stimulatedwith 4 mmol/l H2O2 in eight sickle cell patients and six
healthy controls.2.4. Enzymatic measurement of glutathione
Concentrations of total glutathione and GSSG were determined
according to the methods of Tietze et al. and Sacchetta et al.,
respectively [23,24]. GSH concentrations were calculated from the
difference between total glutathione and GSSG concentrations. The
extracellular samples were ﬁrst centrifuged at 14,500×g for 2 mi-
nutes, after which the extra- and intracellular sampleswere processed
identically. After adding PCA to supernatant (extracellular glutathi-
one) and erythrocyte suspension (intracellular glutathione) to a ﬁnal
concentration of 10% PCA for deproteinization, both samples were
centrifuged at 14,500×g for 2 minutes. The addition of PCA leads to
complete denaturation of proteins and therefore to complete
hemolysis of the cells. This procedure prevents any conversion of
GSH or GSSG. NEM (ﬁnal concentration of 2.5 mM) or water (H2O)
was added to supernatant for measurement of GSSG and total
glutathione concentrations, respectively. NEM irreversibly captures
GSH, leaving GSSG to be measured. After 5 minutes of incubation on
ice with NEM or H2O, potassium phosphate buffer (KPi) (ﬁnal con-
centration 1.4 M) was added to eliminate free NEM and the mixtures
were incubated on ice for 20 minutes. Finally, after adding sufﬁcient
PCA to neutralize the pH, the samples were stored at −20 °C until
further measurements.
Thirty microliters of each sample was added to 200 μl of assay
buffer (110 mM Na2HPO4, 20 mM Na2HPO4 and 5.0 mM EDTA, pH
7.4), containing 0.210 mM NADPH and 0.12 mM DTNB. By adding
glutathione reductase (ﬁnal concentration of 0.2 mg/ml) this cycling
assay was started and changes in absorbance at 410 nm (ΔA410) were
measured with a multifunctional microplate reader (NOVOstar
Microplate Reader, BMG LABTECH, Durham, UK). Kinetic changes in
A410 were converted to concentrations of total glutathione and GSSG
in μmol/l, using a standard curve.
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To determine a potential effect of hemolysis on the degree of
glutathione efﬂux during the oxidative stimulation, concentrations of
intra- and extracellular hemoglobin were measured in samples of each
time point. For measurement of total hemoglobin Triton X 100 was
added to erythrocyte suspension and supernatant to a ﬁnal concentra-
tion of 0.10 % and absorption was measured using NOVOstar.
2.6. MRP1 inhibition
To conﬁrm that GSSG efﬂux takes places via active transport, the
MRP1 inhibitor MK571 (25 μmol/l) was added to erythrocytes of a
healthy control and a sickle cell patient at baseline. Inhibition of GSSG
efﬂux by theMRP1 inhibitor rules out a signiﬁcant role of hemolysis in
GSSG excretion.
2.7. Statistics
As data were not normally distributed, statistical tests for
nonparametric data were used. The Mann–Whitney U-test was used
for comparisons between two groups. Wilcoxon signed rank test was
used for comparisons between different time points within a group.
Pb0.05 was considered statistically signiﬁcant (SPSS 16.0).
3. Results
Baseline intracellular GSH concentrations were comparable be-
tween healthy and sickle erythrocytes and while they did not change
signiﬁcantly in healthy erythrocytes upon addition of DMNQ, GSH
concentrations in sickle erythrocytes decreased signiﬁcantly with this
treatment (Fig. 1A). While comparable at baseline, DMNQ additionFig. 1. Intra- and extracellular GSH and GSSG concentrations in sickle (● solid line; n=1
210 minutes of stimulation with 10 μmol/l DMNQ. (A) Intracellular GSH concentrations at th
indicated times after addition of DMNQ. (C) Extracellular GSH concentrations at the indicate
times after addition of DMNQ. *Pb0.05. Bars indicate means±SEM.resulted in more pronounced increases in GSSG concentrations in
sickle erythrocytes as compared to healthy erythrocytes; after 90
(P=0.013), 150 (Pb0.0001) and 210 minutes of incubation
(P=0.002) (Fig. 1B). Extracellular GSH concentrations increased
only slightly during DMNQ treatment and were comparable between
normal and sickle erythrocytes at each time point (Fig. 1C).
Extracellular GSSG concentrations increased during DMNQ treatment
in both healthy and sickle erythrocytes. However, in parallel with the
higher increases in intracellular concentrations, increases in extracel-
lular GSSG concentrations were signiﬁcantly higher in sickle eryth-
rocytes as compared to healthy erythrocytes (Fig. 1D). While
intracellular GSH/GSSG ratios between sickle and healthy erythro-
cytes were comparable at baseline (10.4±0.76 vs. 11.4±0.63), they
were signiﬁcantly lower in sickle erythrocytes after 210-minute
DMNQ treatment (1.7±0.22 vs. 5.8±1.5, P=0.008). GSSG is actively
excreted out of the erythrocytes by the MRP1 transporter which has a
high afﬁnity for GSSG, whereas GSH is only poorly transported by
MRP1 [25]. The higher GSSG efﬂux in sickle erythrocytes was probably
not due to increased hemolysis since the increases in extracellular
GSH concentrations were signiﬁcantly smaller as compared to
increases in extracellular GSSG concentrations.
Also during H2O2 stimulation, increases in both intracellular and
extracellular GSSG concentrations were signiﬁcantly higher in sickle
erythrocytes than in healthy erythrocytes (Fig. 2A and B).
Within the SCD group, 8 of the 18 patients were on hydroxyurea
therapy. Patients using hydroxyurea had higher fetal hemoglobin (HbF)
percentage than those without hydroxyurea therapy, though the
difference was not statistically signiﬁcant (12.9% (5.3–13.9) vs. 3.8%
(2.0–14.2), P=0.1). Levels of intracellular and extracellular GSSG
concentrations after 210-minute DMNQ treatment tended to be smaller
in erythrocytes of patients using hydroxyurea (67.9±4.2 μmol/l and
21.4±2.8 μmol/l, respectively) than those without hydroxyurea8) and normal erythrocytes (▽, dashed line; n=9) at baseline and after 90, 150 and
e indicated times after addition of DMNQ. (B) Intracellular GSSG concentrations at the
d times after addition of DMNQ. (D) Extracellular GSSG concentrations at the indicated
Fig. 2. Intra- and extracellular GSH and GSSG concentrations in sickle (● solid line; n=8) and normal erythrocytes (▽, dashed line; n=6) at baseline and after 90, 150 and
210 minutes of stimulation with 4 mmol/l H2O2. (A) Intracellular GSH concentrations at the indicated times after addition of H2O2. Note the breaks on the Y-axis. (B) Intracellular
GSSG concentrations at the indicated times after addition of H2O2. Note the breaks on the Y-axis. (C) Extracellular GSH concentrations at the indicated times after addition of H2O2.
(D) Extracellular GSSG concentrations at the indicated times after addition of H2O2. *Pb0.05. Bars indicate means±SEM.
Fig. 3. Intra- and extracellular GSH and GSSG concentrations after DMNQ stimulation in erythrocytes of a sickle cell patient (black lines) and a healthy control (gray lines) without (solid
lines) or with (dashed lines) the MRP1 inhibitor MK571. While GSSG efﬂux is higher in sickle erythrocytes, it is inhibited by MK571 (25 μmol/l) in both sickle and healthy erythrocytes.
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the differences were not statistically signiﬁcant.
Intracellular and extracellular hemoglobin concentrations at
baseline and their changes during 210-minute DMNQ treatment
were comparable between sickle and healthy erythrocytes (2.2±2.3%
vs. 3.9±2.5% and 16.1±6.2% vs. 14.8±4.0% respectively), also ruling
out any signiﬁcant role of hemolysis in GSSG efﬂux.
Adding the MRP1 inhibitor MK571 (25 μmol/l) to erythrocytes of a
sickle cell patient and a healthy control before DMNQ treatment
resulted in inhibition of GSSG efﬂux in both (Fig. 3D), indicating that
GSSG efﬂux is largely mediated by MRP1 [25]. As can be seen in
Fig. 3A, inhibition of MRP1 seems to prevent a decrease in intracellular
GSH concentrations in sickle erythrocytes.4. Discussion
Oxidative stress is an important characteristic of SCD, contributing
signiﬁcantly to disease severity and chronic organ complications [3–6].
Erythrocytes are not only a main source of ROS in SCD but also endure
the brunt of the intracellular oxidative stress [7,26]. Sickle erythrocytes
are characterized by decreased concentrations of GSH [8,27], even
though de novo synthesis is known to be increased [11]. In the present
study we demonstrated that increased GSSG efﬂux from oxidatively
stressed erythrocytes leads to a net loss of glutathione from sickle
erythrocytes.
Upon generation fromGSH, GSSG can be either recycled back to GSH
(mediated by glutathione S-reductase) or excreted to the extracellular
environment by an ATP-dependent transport system located in the
plasma membrane [28–30]. GSSG is an oxidant itself and its enhanced
excretion under oxidative conditions prevents the potentially toxic
effects of intracellular GSSG accumulation [17]. Sulfhydryl groups of
hemoglobin can react with GSSG [31]. If this process contributes
signiﬁcantly, and if it is quantitatively different between normal and
sickle cell erythrocytes, it could play a role in the observed changes in
GSSG efﬂux. However, in both types of erythrocytes the total amount of
thiol equivalents is constant during induced oxidative stress indicating
that glutathionylation does not play a signiﬁcant role in total GSH/GSSG
homeostasis.
GSSG efﬂux is probably driven by higher intracellular concentra-
tions and mediated by the ABC transporter MRP1 which is also
important in elimination of xenobiotics [18,19]. This was conﬁrmed in
our study where adding an MRP1 inhibitor to erythrocytes blocked
DMNQ induced GSSG efﬂux in both sickle and healthy erythrocytes.
Inhibition of MRP1 also seemed to prevent a DMNQ induced decrease
in intracellular GSH concentrations. This was conﬁrmed in an animal
study where complete inhibition of MRP1 transport in MRP1 knock-
out mice resulted in increased intracellular GSH concentrations [32].
Future animal studies need to elucidate whether MRP1 inhibition and
the resulting increase in intracellular GSH concentrations would
ameliorate or deteriorate oxidative stress and hemolysis in sickle
erythrocytes.
Interestingly, while in healthy erythrocytes the concentrations of
intracellular GSH during oxidative stimulation remained unchanged,
they decreased signiﬁcantly in sickle erythrocytes, indicating a higher
GSH consumption in sickle erythrocytes. Even though the exact
mechanism remains to be elucidated, two processesmay contribute to
this phenomenon. First, sickle erythrocytes have a higher intrinsic
production of ROS and a less optimal antioxidant status, which leads
to enhanced GSSG production [33–35]. Second, the increased
formation of GSSG drives a resultant enhanced GSSG efﬂux in sickle
erythrocytes which prevents GSSG from being recycled to GSH by
glutathione S-reductase, leading to net loss of thiol equivalents from
the cells. This is especially important under conditions of elevated
oxidative stress, such as vaso-occlusive painful crisis with ischemia–
reperfusion, acute chest syndrome and accelerated hemolysis [1,2].Of the eighteen sickle cell patients of our study, eight were on
hydroxyurea therapy. Hydroxyurea is a cytostatic agent that inhibits
myelopoiesis and its therapeutic effect is thought to be primarily
based on an increased synthesis of HbF [36,37]. A higher percentage of
HbF in sickle erythrocytes results in a lower intracellular HbS
concentration and thus decreased production of ROS by the
autoxidative HbS [7,38]. The anti-oxidative effect of hydroxyurea is
also suggested by our data as the erythrocytes of patients using
hydroxyurea tended to have smaller increases in intracellular and
extracellular GSSG concentrations compared to erythrocytes of
patients not using hydroxyurea, even though the differences were
not statistically signiﬁcant.
Oxidative stress might increase during acute vaso-occlusive
painful crisis with ensuing ischemia–reperfusion injury. Whether a
painful crisis causes increased GSSG production and efﬂux in sickle
erythrocytes remains to be elucidated.
Sickle cell disease is characterized by chronic hemolysis and its
role in higher GSSG efﬂux in sickle erythrocytes should be taken in
consideration. However, the increases in extracellular concentrations
of GSHwere comparable between sickle and healthy erythrocytes and
much lower than GSSG concentrations, arguing against a signiﬁcant
role of hemolysis in higher GSSG efﬂux from sickle erythrocytes.
GSH has a much lower afﬁnity to MRP1 transporters and since its
intracellular concentrations are signiﬁcantly higher than intracellular
GSSG concentrations, any signiﬁcantly higher increases in extracellu-
lar concentrations of GSH in sickle erythrocytres would be primarily
due to hemolysis. Furthermore, concentrations of intra- and extra-
cellular hemoglobin and their changes during DMNQ stimulation
were comparable between the sickle and healthy erythrocytes, ruling
out any signiﬁcant role of hemolysis in the increased GSSG efﬂux in
sickle erythrocytes.
In contrast to previous reports of lower erythrocyte concentrations
of total glutathione and GSH [11,27], we did not observe a difference in
glutathione concentrations between sickle and healthy erythrocytes.
The fact that we only used very fresh erythrocyte preparations may
contribute to this lack of difference, as consumption of glutathione
is higher in sickle erythrocytes and cannot be replenished in vitro.
However, it is also possible that the sample size of this study might be
too low to detect any statistically signiﬁcant differences in intracellular
glutathione concentrations. Our data do suggest, however, that our
hypothesis is relevant: we show that equal stimuli for oxidative stress
(such as DMNQ or H2O2) lead to higher loss of intracellular glutathione
in sickle erythrocytes as compared to healthy erythrocytes. Hence, also
in vivo increases in oxidative stress are likely to lead to more loss of
intracellular glutathione in sickle cell patients as compared to healthy
controls.
In conclusion, GSSG efﬂux in sickle erythrocytes is increased and
could play an important role in glutathione depletion in these cells.
This loss of intracellular glutathione possibly diminishes the antiox-
idant defense of erythrocytes rendering them more susceptible to
oxidative damage.References
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